John G. Kuhn

12.3k total citations
188 papers, 8.8k citations indexed

About

John G. Kuhn is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, John G. Kuhn has authored 188 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Molecular Biology, 82 papers in Oncology and 69 papers in Genetics. Recurrent topics in John G. Kuhn's work include Glioma Diagnosis and Treatment (49 papers), Cancer Treatment and Pharmacology (44 papers) and Cancer therapeutics and mechanisms (41 papers). John G. Kuhn is often cited by papers focused on Glioma Diagnosis and Treatment (49 papers), Cancer Treatment and Pharmacology (44 papers) and Cancer therapeutics and mechanisms (41 papers). John G. Kuhn collaborates with scholars based in United States, Canada and France. John G. Kuhn's co-authors include Daniel D. Von Hoff, Michael D. Prados, Timothy F. Cloughesy, Howard A. Burris, Patrick Y. Wen, Kathleen R. Lamborn, Minesh P. Mehta, Geoffrey R. Weiss, Susan M. Chang and H. Ian Robins and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

John G. Kuhn

186 papers receiving 8.5k citations

Peers

John G. Kuhn
Athanassios P. Kyritsis United States
Gilles Vassal France
Luigi Maria Larocca Italy
Clinton F. Stewart United States
Joel M. Reid United States
M. Eileen Dolan United States
Nicolás André France
Jesús García‐Foncillas Spain
Bin Peng China
Alan K. Burnett United Kingdom
Athanassios P. Kyritsis United States
John G. Kuhn
Citations per year, relative to John G. Kuhn John G. Kuhn (= 1×) peers Athanassios P. Kyritsis

Countries citing papers authored by John G. Kuhn

Since Specialization
Citations

This map shows the geographic impact of John G. Kuhn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John G. Kuhn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John G. Kuhn more than expected).

Fields of papers citing papers by John G. Kuhn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John G. Kuhn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John G. Kuhn. The network helps show where John G. Kuhn may publish in the future.

Co-authorship network of co-authors of John G. Kuhn

This figure shows the co-authorship network connecting the top 25 collaborators of John G. Kuhn. A scholar is included among the top collaborators of John G. Kuhn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John G. Kuhn. John G. Kuhn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Dávila‐González, Daniel, Dong Soon Choi, Roberto R. Rosato, et al.. (2018). Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer. Clinical Cancer Research. 24(5). 1152–1162. 68 indexed citations
3.
Warnken, Zachary N., Yajie Zhang, Daniel A. Davis, et al.. (2018). A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier. Pharmaceutics. 10(2). 60–60. 23 indexed citations
4.
Warnken, Zachary N., Hugh D. C. Smyth, Daniel A. Davis, et al.. (2018). Personalized Medicine in Nasal Delivery: The Use of Patient-Specific Administration Parameters To Improve Nasal Drug Targeting Using 3D-Printed Nasal Replica Casts. Molecular Pharmaceutics. 15(4). 1392–1402. 66 indexed citations
5.
Sawas, Ahmed, Charles M. Farber, Marshall T. Schreeder, et al.. (2017). A phase 1/2 trial of ublituximab, a novel anti‐ CD 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. British Journal of Haematology. 177(2). 243–253. 61 indexed citations
6.
Wang, Chen-Pin, Donna M. Lehman, John G. Kuhn, et al.. (2016). Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes. Cancer Prevention Research. 9(10). 779–787. 20 indexed citations
7.
Kelly, Kevin R., Avvaru N. Suhasini, An-Ping Lin, et al.. (2016). Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies. Clinical Cancer Research. 23(5). 1186–1192. 27 indexed citations
8.
Prados, Michael D., Sara A. Byron, Nhan L. Tran, et al.. (2015). Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncology. 17(8). 1051–1063. 157 indexed citations
9.
Iwamoto, Fábio M., Kathleen R. Lamborn, John G. Kuhn, et al.. (2011). A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro-Oncology. 13(5). 509–516. 94 indexed citations
10.
Prados, Michael D., Kathleen R. Lamborn, W. K. Alfred Yung, et al.. (2006). A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1. Neuro-Oncology. 8(2). 189–193. 187 indexed citations
11.
Lassman, Andrew B., Michael R. Rossi, Lauren E. Abrey, et al.. (2005). Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clinical Cancer Research. 11(21). 7841–7850. 201 indexed citations
12.
Mita, Monica, Eric K. Rowinsky, John G. Kuhn, et al.. (2005). A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense™, G3139) and irinotecan in patients with metastatic colorectal cancer. Annals of Oncology. 17(2). 313–321. 36 indexed citations
13.
Rothenberg, Mace L., John G. Kuhn, Larry J. Schaaf, et al.. (2001). Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Annals of Oncology. 12(11). 1631–1641. 32 indexed citations
14.
Harlow, Seth P., David N. Krag, Takashi Ashikaga, et al.. (2001). Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study. Melanoma Research. 11(1). 45–55. 63 indexed citations
15.
Burris, Howard A., Ahmad Awada, John G. Kuhn, et al.. (1994). Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anti-Cancer Drugs. 5(4). 394–402. 40 indexed citations
16.
Cobb, Patrick, Donna Degen, Gary M. Clark, et al.. (1994). Activity of DMP 840, a New Bis-naphthalimide, on Primary Human Tumor Colony-Forming Units. JNCI Journal of the National Cancer Institute. 86(19). 1462–1465. 13 indexed citations
17.
Burris, Howard A., John G. Kuhn, Lee Smith, et al.. (1993). Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.. Journal of Clinical Oncology. 11(5). 950–958. 120 indexed citations
18.
Rodriguez, Gladys, Thomas D. Brown, Frank M. Balis, et al.. (1993). A phase I trial of trimetrexate (NSC352122) on a daily × 5 schedule in patients with refractory adult leukemia. Anti-Cancer Drugs. 4(2). 163–166. 3 indexed citations
19.
Havlin, Kathleen A., John G. Kuhn, John B. Craig, et al.. (1991). Phase I evaluation of 773U82 HCI, a member of a new class of DNA intercalators. Anti-Cancer Drugs. 2(4). 357–364.
20.
Craig, John B., John G. Kuhn, Jay Luther, et al.. (1988). Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.. PubMed. 48(16). 4706–10. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Athanassios P. Kyritsis Breakdown of academic impact, for papers by Gilles Vassal Breakdown of academic impact, for papers by Luigi Maria Larocca Breakdown of academic impact, for papers by Clinton F. Stewart Breakdown of academic impact, for papers by Joel M. Reid Breakdown of academic impact, for papers by M. Eileen Dolan Breakdown of academic impact, for papers by Nicolás André Breakdown of academic impact, for papers by Jesús García‐Foncillas Breakdown of academic impact, for papers by Bin Peng Breakdown of academic impact, for papers by Alan K. Burnett
Rankless by CCL
2026